SciELO - Scientific Electronic Library Online

 
vol.22 número5Síndrome de Guillain-Barré muy temprano: características clínicas, hallazgos electrofisiológicos y resultado funcional a corto plazoAlteraciones de la expresión génica de la diabetes mellitus en el desarrollo y progresión de la enfermedad de Alzheimer: el vínculo de la vía PI3K/Akt índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Revista mexicana de neurociencia

versión On-line ISSN 2604-6180versión impresa ISSN 1665-5044

Resumen

BOTELLO-VILLAGRANA, Fernando  y  MARTINEZ-RAMIREZ, Daniel. Mucuna pruriens as adjunct therapy to levodopa in advanced Parkinson's disease. Rev. mex. neurocienc. [online]. 2021, vol.22, n.5, pp.180-183.  Epub 25-Oct-2021. ISSN 2604-6180.  https://doi.org/10.24875/rmn.21000010.

Background:

Parkinson's disease (PD) is a neurodegenerative disorder whose treatment in advanced stages is often complex and challenging. The treatment goal at this stage is to provide greater clinical stability, with less "off" time and longer "on" time. Mucuna pruriens (MP) is a legume plant traditionally used in Ayurvedic medicine for Parkinsonian-type diseases. This plant contains a diversity of elements, among which levodopa stands out.

Objective:

We explored the effect of MP as adjunct therapy to levodopa in a PD patient.

Methods:

We report the case of a 42-year-old woman with PD in advanced stages due to motor fluctuations and dyskinesias. Due to the progression of her disease, the limitations that it generates and the economic inability to opt for other therapies such as surgical treatments, we used MP as an adjunct therapy to levodopa.

Results:

MP produces a clinical motor effect similar to conventional levodopa. MP shortened the time to reach the "on" state and prolonged this state without exacerbating dyskinesias. Psychiatric side effects were observed only with high dosages of MP.

Conclusions:

MP shows to be a promising adjunct therapy to levodopa in advanced PD patients without access to other conventional therapies.

Palabras llave : Parkinson's disease; Mucuna pruriens; Levodopa; Motor fluctuations; Dyskinesia.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )